NEOT Neothetics, Inc.

+0.18  (8%)
Previous Close 2.28
Open 2.26
Price To book 2.65
Market Cap 34.02M
Shares 13,829,000
Volume 311,970
Short Ratio 0.51
Av. Daily Volume 277,546

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due June 2017.
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
Reduction of central abdominal bulging